Novel Variant-Specific COVID-19 Vaccine NVX-CoV2515 Associated With Superior Neutralizing Antibody Response Against Omicron BA.1, Research Indicates

January 04, 2024

Infectious Disease Advisor (1/3, Nye) reports, “The novel variant-specific COVID-19 vaccine NVX-CoV2515 is associated with a superior neutralizing antibody response against Omicron BA.1 when compared with the prototype vaccine NVX-CoV2373.” The findings were published in The Journal of Infectious Diseases.